IBB CL Stock Overview
An exchange traded fund launched by BlackRock, Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
iShares Trust - iShares Biotechnology ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$130,670.00 |
| 52 Week High | US$135,130.00 |
| 52 Week Low | US$122,270.00 |
| Beta | 0.73 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 21.20% |
| 3 Year Change | 21.20% |
| 5 Year Change | n/a |
| Change since IPO | 16.96% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IBB CL | CL Capital Markets | CL Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 1.8% |
| 1Y | 21.2% | -4.3% | 13.1% |
Return vs Industry: IBB CL exceeded the CL Capital Markets industry which returned -4.3% over the past year.
Return vs Market: IBB CL exceeded the CL Market which returned 13.1% over the past year.
Price Volatility
| IBB CL volatility | |
|---|---|
| IBB CL Average Weekly Movement | 0% |
| Capital Markets Industry Average Movement | 2.8% |
| Market Average Movement | 2.3% |
| 10% most volatile stocks in CL Market | 4.4% |
| 10% least volatile stocks in CL Market | 1.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine IBB CL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | n/a | www.ishares.com/us/products/239699/ishares-nasdaq-biotechnology-etf |
iShares Trust - iShares Biotechnology ETF is an exchange traded fund launched by BlackRock, Inc. It is managed by BlackRock Fund Advisors. It invests in public equity markets of the United States. It invests in stocks of companies operating across biotechnology sectors.
iShares Trust - iShares Biotechnology ETF Fundamentals Summary
| IBB CL fundamental statistics | |
|---|---|
| Market cap | CL$6.43t |
| Earnings (TTM) | CL$352.68b |
| Revenue (TTM) | CL$53.11b |
18.2x
P/E Ratio121.1x
P/S RatioIs IBB CL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBB CL income statement (TTM) | |
|---|---|
| Revenue | US$54.08m |
| Cost of Revenue | US$0 |
| Gross Profit | US$54.08m |
| Other Expenses | -US$305.06m |
| Earnings | US$359.15m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.60 |
| Gross Margin | 100.00% |
| Net Profit Margin | 664.08% |
| Debt/Equity Ratio | 10.8% |
How did IBB CL perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield5%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 03:06 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
iShares Trust - iShares Biotechnology ETF is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|